Signaling pathway of insulin-like growth factor-II as a target of molecular therapy for hepatoblastoma

Figure 4 LY294002 or Wortmannin, selective inhibitors of PI3 kinase, or PD98059, a selective inhibitor of MAP kinase, was added to the medium 30 min prior to the stimulation with IGF-II (200 μg/L). LY294002 (A) and Wortmannin (B) suppressed the proliferation of Huh-6 and HepG while PD98059 suppressed HepG2 (C)